Truist Securities Maintains Hold on Edwards Lifesciences, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Edwards Lifesciences and lowered its price target from $71 to $70.
October 25, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has maintained a Hold rating on Edwards Lifesciences and slightly lowered the price target from $71 to $70, indicating a cautious outlook.
The Hold rating suggests that the analyst does not see significant upside or downside in the stock, while the slight reduction in the price target indicates a marginally more cautious outlook. This is likely to have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100